Relay Therapeutics vs Surrozen
RLAY and SRZN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RLAY and SRZN compare
Relay Therapeutics is the larger company, worth 11 times as much as Surrozen ($4.0B against $372M).
Relay Therapeutics grew revenue faster over the last twelve months (23.9% versus −8.8% for Surrozen).
Relay Therapeutics keeps more of each dollar of sales as profit, with a net margin of −2837% compared with −2885% at Surrozen.
Relay Therapeutics scores higher on the StockData Score (10 against 5 for Surrozen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RLAY | SRZN |
|---|---|---|
| Size and price | ||
| Market cap | $4.0B | $372M |
| Share price | $18.09 | $31.61 |
| Change, 1 year | 193% | 144% |
| Change, 5 years | −47.5% | −77.1% |
| Beta (5Y) | 1.94 | 0.52 |
| Employees | 192 | 44 |
| StockData Score | ||
| Total score | 10 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 2 (better) | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 383× | 32.3× (better) |
| P/B | 4.8× | – |
| FCF yield | – | −9.4% |
| Growth | ||
| Revenue growth (TTM) | 23.9% (better) | −8.8% |
| Revenue growth, 5Y average | −28.6% | – |
| Profitability | ||
| Operating margin | −3095% | −385% (better) |
| Net margin | −2837% (better) | −2885% |
| FCF margin | – | −304% |
| Return on equity | −41.2% | – |
| Return on invested capital | −41.8% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 14.62 (better) | 12.14 |
| Altman Z-score | 25.18 (better) | −6.78 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | – | −0.94% |
| Shareholder yield | 0.00% (better) | −0.94% |
| Ownership | ||
| Held by institutions | 113% | 91.3% |
| Held by insiders | 24.5% | 44.5% |
| Insider net buying, 12 months | −$129M | $1.6M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 26.4% | 49.6% |
Go deeper
- RLAY stock overview
- RLAY income statement
- RLAY valuation and score
- SRZN stock overview
- SRZN income statement
- SRZN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.